Community-acquired AKI was associated with lower mortality than hospital-acquired AKI (45% vs 62.9%; HR for HA-AKI 1.8; 95% CI 1.44-2.13; P<0.001) over 14 months of follow-up.
Cohort (n=15,976)
Yes
Effect estimate: HR 1.8 (95% CI 1.44-2.13)
Absolute Event Rate: 45% vs 62.9%
p-value: p=<0.001
BACKGROUND AND OBJECTIVE: Compared with AKI in hospitalized patients, little is known about patients sustaining AKI in the community and how this differs from AKI in hospital. This study compared epidemiology, risk factors, and short- and long-term outcomes for patients with community-acquired (CA) and hospital-acquired (HA) AKI. DESIGN, SETTING, PARTICIPANTS, P<0.001] for HA-AKI group). Mortality for the CA-AKI group was 45%; 43.7% of these deaths were acute in-hospital deaths. Mortality for the HA-AKI group was 62.9%, with 68.1% of these deaths being acute in-hospital deaths. Renal referral rates were low across the cohorts (8.3%). Renal outcomes were similar in both CA-AKI and HA-AKI groups, with 39.4% and 33.6% of patients in both groups developing de novo CKD or progression of preexisting CKD within 14 months, respectively. CONCLUSION: Patients with CA-AKI sustain more severe AKI than patients with HA-AKI. Despite having risk factors similar to those of patients with HA-AKI, patients with CA AKI have better short- and long-term outcomes.
Wonnacott et al. (Fri,) conducted a cohort in Acute Kidney Injury (AKI) (n=15,976). Community-acquired AKI vs. Hospital-acquired AKI was evaluated on Mortality (HR 1.8, 95% CI 1.44-2.13, p=<0.001). Community-acquired AKI was associated with lower mortality than hospital-acquired AKI (45% vs 62.9%; HR for HA-AKI 1.8; 95% CI 1.44-2.13; P<0.001) over 14 months of follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: